Bio-India Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.25 Cr
as on 15-11-2024
- Paid Up Capital ₹ 6.70 M
as on 15-11-2024
- Company Age 24 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 4.15 Cr
as on 15-11-2024
- Revenue 4.57%
(FY 2023)
- Profit -73.35%
(FY 2023)
- Ebitda 239.60%
(FY 2023)
- Net Worth -1.85%
(FY 2023)
- Total Assets 15.50%
(FY 2023)
About Bio-India Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.25 Cr and a paid-up capital of Rs 6.70 M.
The company currently has active open charges totaling ₹4.15 Cr.
Savio Dcosta and Prabhakar Vithal serve as directors at the Company.
- CIN/LLPIN
U15100MH2000PTC127200
- Company No.
127200
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
14 Jun 2000
- Date of AGM
29 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Bio-India Pharma Private Limited offer?
Bio-India Pharma Private Limited offers a wide range of products and services, including Homeopathic Medicines & Remedies, Homeopathic Drugs, Health Conditions, Pain Relief, Homeopathy Medicines, Dilutions, Bio Combinations, Fever.
Who are the key members and board of directors at Bio-India Pharma?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Savio Dcosta  | Whole-Time Director | 14-Jun-2000 | Current |
| Prabhakar Vithal | Director | 14-Jun-2000 | Current |
Financial Performance and Corporate Structure Insights of Bio-India Pharma.
Bio-India Pharma Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 4.57% increase. The company also saw a substantial fall in profitability, with a 73.35% decrease in profit. The company's net worth dipped by a decrease of 1.85%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Bio-India Pharma?
In 2023, Bio-India Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Herbamed Naturals Private LimitedActive 24 years 10 monthsSavio Dcosta and Prabhakar Vithal are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Canara Bank Creation Date: 04 Jun 2021 | ₹9.33 M | Open |
Sidbi Creation Date: 14 Oct 2020 | ₹5.00 M | Open |
Canara Bank Creation Date: 23 Jun 2020 | ₹0.13 M | Open |
How Many Employees Work at Bio-India Pharma?
Bio-India Pharma has a workforce of 64 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Bio-India Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Bio-India Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
